Full Text
PCN362 DO ANTICANCER DRUGS ENTERING THE FRENCH MARKET PROVIDE SIGNIFICANT EVIDENCE OF THEIR CLINICAL EFFICACY?

Abstract

Authors

O. van Hinloopen I. Borget

Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×